- The use of erenumab is not associated with an increased risk for vascular adverse events (AEs) or BP changes compared with placebo in patients with migraine.
- No association seen even in patients treated with acute migraine-specific medication or with other vascular risk factors.
Why this matters
- Erenumab blocks a calcitonin gene-related peptide receptor, which can mediate vasodilation.
- Meta-analysis identified 4 double-blind, placebo-controlled studies of erenumab and their open-label extensions in patients with chronic or episodic migraine.
- Treatment groups: placebo (n=1043), erenumab 70 mg (n=893), or erenumab 140 mg (n=507).
- Funding: Amgen Inc.; Novartis.
- During 12 weeks of double-blind treatment, hypertension-related AE rates were 0.9% (placebo), 0.8% (erenumab 70 mg), and 0.2% (erenumab 140 mg).
- 18 patients had AEs and fulfilled criteria for adjudication, of whom 4 patients had events of cardiovascular origin.
- Similar AE incidences were noted among users of acute migraine-specific medications:
- Any AEs: placebo, 49.6%; erenumab 70 mg, 47%; erenumab 140 mg, 46.9%.
- Serious AEs: placebo, 1.9%; erenumab 70 mg, 2.1%; erenumab 140 mg, 1.5%.
- Regardless of the number of vascular risk factors, AE incidences were similar across placebo and erenumab groups.
- Open-label study.
Coauthored with Chitra Ravi, MPharm